Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are: Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users? What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users? Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Official Title
-----------------
Parents' Enhanced Reminder Intervention to Improve Children's Timely Completion of Immunization Series of Pneumococcal Vaccine at the 12-month's Visit

Conditions
-----------------
Pneumococcal Vaccines, Immunization Coverage

Intervention / Treatment
-----------------
* Other: Enhanced reminders
* Other: Standard CANImmunize notifications


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria To be included in the study, CANImmunize account holders must have: Enabled the reception to receive emails from CANImmunize, and Record(s) for an infant aged between 10- and 11-months, who have already received the earlier doses of the pneumococcal vaccine in accordance with their provincial/territorial routine immunization schedule. Exclusion Criteria The account holder (parent, or guardian of the child) has an inactive or undelivered email address, or No record(s) for an infant aged 10- and 11-months, or The record for the 10- or 11-month-old indicates that he/she has not received the prior pneumococcal vaccine doses.

Ages Eligible for Study
-----------------
Minimum Age: 10 Months
Maximum Age: 11 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Enhanced reminders<br> | Other: Enhanced reminders<br>* The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically: Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine, Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit<br>|
| Active Comparator: Standard notifications<br> | Other: Standard CANImmunize notifications<br>* Push notifications at two time points: two weeks prior to the immunization due date one week after the immunization due date<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Receipt of 12-month pneumococcal vaccine | Receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record | 12 months of age | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Timeliness of 12-month pneumococcal vaccine | Age at receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record | 12-13 months of age will be considered as timely, after 13 months considered late | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vaccine coverage, Vaccine uptake